CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
IPO Year: 1997
Exchange: NASDAQ
Website: ctibiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2022 | $13.00 | Outperform | SVB Leerink |
| 9/1/2022 | $13.00 | Buy | Jefferies |
| 7/7/2022 | $10.00 | Outperform | Cowen |
| 3/2/2022 | $4.00 → $5.00 | Market Outperform | JMP Securities |
| 3/2/2022 | $5.00 → $8.00 | Buy | Needham |
| 12/1/2021 | $6.00 → $5.00 | Buy | Needham |
| 8/9/2021 | $7.00 | Buy | BTIG Research |
SVB Leerink initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $13.00
Jefferies initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $13.00
Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00
JMP Securities reiterated coverage of CTI BioPharma with a rating of Market Outperform and set a new price target of $5.00 from $4.00 previously
Needham reiterated coverage of CTI BioPharma with a rating of Buy and set a new price target of $8.00 from $5.00 previously
Needham reiterated coverage of CTI BioPharma with a rating of Buy and set a new price target of $5.00 from $6.00 previously
BTIG Research initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $7.00
Stifel initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $5.50
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
15-12G - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)